SCT510A (bevacizumab intravitreal biosimilar)
/ Sinocelltech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 16, 2023
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
(clinicaltrials.gov)
- P3 | N=446 | Recruiting | Sponsor: Sinocelltech Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2022 ➔ Feb 2023
Enrollment open • Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
July 29, 2022
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
(clinicaltrials.gov)
- P3 | N=446 | Not yet recruiting | Sponsor: Sinocelltech Ltd.
New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
September 25, 2020
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
(clinicaltrials.gov)
- P1/2; N=66; Not yet recruiting; Sponsor: Sinocelltech Ltd.
Clinical • New P1/2 trial • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 3
Of
3
Go to page
1